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Objectives. This study assessed the safety and efficacy of 
combined flecainide and amiodarone therapy in controlling re- 
fractory tachyarrhythmias in infants. 
Background. Single-drug as well as standard combination 
medical therapy for tachyarrhythmias n infants sometimes fails. 
In those cases, one may consider interventional therapy. However, 
this option may carry a high risk of morbidity and mortality in 
infants. The natural history of tachyarrhythmias in infants often 
favors eventual resolution and reinforces the importance of 
selecting an effective medical regimen. 
Methods. We performed a retrospective analysis of nine infants 
(median age 2 months) who received combined flecainide and 
amiodarone therapy for attempted control of refractory tachy- 
arrhythmias. Trough serum drug levels of flecainide were moni- 
tored, and 24-h ambulatory electrocardiographic monitoring was 
used to determine fficacy of therapy. 
Results. Single-drug treatment with flecainide or amiodarone 
failed in all of the infants studied. An average of four drugs failed 
(range one to six) before administration of combined flecainide 
and amiodarone therapy. During combined therapy, the flecainide 
dose was 70 to 110 mg/m 2per day, and that for amiodarone was 
7.5 to 13.5 mg/kg per day for a mean (-+SD) of 9 -+ 2 days to load 
and 5 to 12 mg/kg per day as maintenance. Successful control of 
tachyarrhythmias was demonstrated in seven (78%) of nine 
infants (95% confidence interval 46% to 99%) (three of three with 
congenital junctional ectopic tachycardia, three of three with 
supraventricular tachycardia nd one of three with ventricular 
tachycardia). During combined therapy, flecainide trough levels 
ranged from 350 to 731 ng/ml. Corrected QT intervals varied from 
0.440 to 0.488 ms. No proarrhythmia occurred. None of the infants 
required a pacemaker, and all had normal eft ventricular dimen- 
sions and fractional shortening by echocardiography. Eight of 
nine infants had a structurally normal heart. One infant had 
surgical correction of an atrioventricular septal defect. 
Conclusions. Combination therapy with flecainide and amioda- 
rone appears to be safe and effective in controlling refractory 
tachyarrhythmias in infants. The combination of flecainide and 
amiodarone may obviate the need for early interventional therapy 
or may allow delay until the child is older. 
(J Am Coll Cardiol 1995;25:1195- 8) 
Conventional medical therapy in infants with supraventricular 
tachycardias usually includes digoxin, propranolol and flecain- 
ide used as single agents or in combination. In addition, 
amiodarone may be considered a second-line conventional 
agent by some. For the vast majority of infants these drugs 
successfully control their tachycardia until it no longer occurs 
without antiarrhythmic drugs or until the child is of an age and 
size where interventional therapy with transcatheter radiofre- 
quency ablation is considered safe (1). Currently, most centers 
advise against he use of transcatheter radiofrequency ablation 
in infants unless all attempts at medical management of the 
tachycardia re unsuccessful (2-5). 
Likewise, infants with ventricular tachycardia often respond 
to therapy with propranolol, mexiletine, flecainide or amioda- 
rone. In some cases of incessant ventricular tachycardia, 
surgical intervention is necessary and may be life-saving, but 
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the procedure is not without risk and is generally reserved for 
infants in whom medical therapy has failed (6). 
In managing infants with supraventricular tachycardia, it is 
important o understand that natural history favors eventual 
resolution in 60% to 90% (7-9). In infants with ventricular 
tachycardia and no underlying heart disease, the majority have 
resolution of their tachycardia (10,11). Thus, if a medical 
regimen can safely and effectively suppress symptomatic 
tachyarrhythmias n this age group, interventional therapy may 
not be necessary. 
Flecainide and amiodarone used independently have 
proved effective in the treatment of many tachyarrhythmias n 
children (12-2l). However, single-drug therapy with each of 
these agents may not always provide acceptable arrhythmia 
control. Studies in adults have demonstrated safe and effective 
control of both supraventricular nd ventricular tachycardia 
with combined flecainide and amiodarone therapy (22-25). 
Methods  
We retrospectively analyzed the clinical records of nine 
infants who received combined flecainide and amiodarone 
therapy. Twenty-four-hour ambulatory electrocardiographic 
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Table 1. Clinical and Arrhythmia Characteristics of Nine Study Infants 
Pt No. Age/Gender Cardiac Anatomy Arrhythmia Previous Therapy 
1 9 d/F Normal AET Dig, Prop, Flec, Amio 
2 3.5 mo/M Normal AVRT Dig, Prop, Flec, Amio 
3 4.5 mo/F Normal CAT Dig, Proc, Flec, Prop, Amio 
4 2 wk/F Normal C JET Prop, Flec 
5 2 wk/M Normal C JET Flec 
6 2 wk/M Normal C JET Dig, Prop, Flec 
7 6 d/M "Normal," fibrous VT Dig, Lido, Proc, Esmo, 
plaque Amio (IV) 
8 8 mo/F p/o AVSD VT Lido, Prop, Proc, Flec, Mex, 
Amio 
9 17 mo/F "Normal," myocardial VT Prop, Proc, Lido, Amio (IV) 
tumor 
AET atrial cctopic tachycardia; Amio = amiodarone; AVRT atrioventricular reciprocating tachycardia; 
AVSD - atrioventricular septal defect; CAT = chaotic atrial tachycardia; CJET - congenital junctional ectopic 
tachycardia; Dig digoxin; Esmo = esmolol; F female; Flec flecainide; Lido = lidocaine; M male; Mex = 
mexiletine; p/o = postoperative: Proc = procainamide; Prop = propranolol; Pt - patient; VT - ventricular tachycardia. 
(ECG) monitoring was used to define efficacy. For supraven- 
tricular tachycardia and congenital junctional ectopic tachycar- 
dia, efficacy of therapy was considered achieved if the tachy- 
cardia was eliminated or was slowed to a clinically tolerable 
rate. In infants with ventricular tachycardia, efficacy was con- 
sidered achieved if the tachycardia was eliminated. Fluores- 
cence polarization immunoassay was used to measure trough 
serum drug levels of flecainide 5 half-lives after initiation of 
therapy and after each dose adjustment. Echocardiograms to
assess ventricular function were obtained before and during 
combination therapy. Left ventricular dimensions and frac- 
tional shortening were calculated as previously described (26). 
Surface ECGs were reviewed before and during combination 
therapy. The corrected QT interval (QTc) was calculated 
by normalizing the QT interval for heart rate (QTc = 
QT/,/RR) (27). 
Results  
Patient profile. The age of the infants at diagnosis of their 
tachyarrhythmia ranged from 6 days to 17 months (median 2 
months) (Table 1). Eight of 9 had a structurally normal heart 
as determined by echocardiography. One infant had surgical 
correction of an atrioventricular (AV) septal defect. Three of 
the nine infants had supraventricular tachycardia, including 
one each with atrial ectopic tachycardia, AV reciprocating 
tachycardia and chaotic atrial tachycardia. Three infants had 
congenital junctional ectopic tachycardia, nd three had ven- 
tricular tachyeardia. An average of four antiarrhythmic agents 
(range one to six) failed before the combined use of flecainide 
and amiodarone. Treatment with flecainide or amiodarone as 
single-drug therapy failed in all infants tudied. 
Dosages of flecainide and amiodarone. During combined 
therapy, the dose of flecainide was 70 to 110 mg/m 2per day. 
The starting dose was generally 70 mg/m 2per day for those 
infants already receiving amiodarone therapy. For infants who 
had amiodarone added to their therapy, the flecainide dose 
was decreased by one-third. Dosages were adjusted to achieve 
serum trough levels of 200 to 800 ng/ml, although serum levels 
<200 ng/ml were accepted if clinical efficacy was met. Flecain- 
ide serum trough levels ranged from 350 to 731 ng/ml. Mean 
dose of amiodarone was 10.6 mg/kg body weight per day (range 
7.5 to 13.5) for 9 _+ 2 days while loading and 6.7 mg/kg per day 
(range 5 to 12) as maintenance. Two of the infants with 
incessant ventricular tachycardia received intravenous amioda- 
rone as previously described (28). 
Response to fleeainide and amiodarone therapy. The com- 
bination of flecainide and amiodarone (Table 2) achieved 
efficacy in seven (78%) of the nine infants (95% confidence 
interval 46% to 99%). Efficacy was generally observed within 1 
to 5 days after initiation of combined therapy. Three of three 
infants with supraventricular tachycardia nd three of three 
infants with congenital junctional ectopic tachycardia had 
successful control of their tachyarrhythmia. P tient 5 had 
congenital junctional ectopic tachycardia atrates of 380 to 400 
beats/rain. This infant was not maintained in sinus rhythm but 
was asymptomatic once slowing of the junctional tachycardia 
rate to 140 to 150 beats/min was achieved. All of the other 
infants with supraventricular nd congenital junctional ectopic 
tachycardia established sinus rhythm and experienced no 
tachycardia episodes during combined therapy. 
Only one of three infants with ventricular tachycardia 
responded to flecainide and amiodarone therapy. One infant 
(Patient 7) developed ventricular tachycardia 2 months after 
surgical repair of an AV septal defect. After therapy with 
propranolol, procainamide, flecainide, mexiletine and mexil- 
etine with amiodarone failed, she responded to flecainide and 
amiodarone combined. Another infant (Patient 8) developed 
incessant ventricular tachycardia at 6 days of age and had a 
structurally normal heart by echocardiography. The combina- 
tion of flecainide and intravenous amiodarone failed to control 
his tachyarrhythmia but slowed the rate. Because of progres- 
sive myocardial decompensation, perative mapping was per- 
formed, identifying a fibrous plaque on the right ventricular 
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Table 2. Response and Follow-Up Information 
Pt No. Arrhythmia Efficacy Length of Rx Current Rx Outcome 
l AET Yes 7 mo None NSR 
2 AVRT Yes 8 mo Flec NSR 
3 CAT Yes 6 mo Flec NSR 
4 C JET Yes 4 mo None NSR 
5 CJET Yes 3 mo Amio AJR 140-150 beats/min 
6 C JET Yes 10 mo None NSR 
7 VT No 12 h N/A Fibrous plaque resection; 
died 2 days p/o (no VT) 
8 VT Yes 17 mo Flec/Amio NSR 
9 VT No 1 wk None Tumor resection; NSR 
AJR = accelerated junctional rhythm; N/A = not applicable; NSR - normal sinus rhythm; other abbreviations a in 
Table 1. 
free wall. After excision of the plaque, the infant was in sinus 
rhythm. This infant died on the second postoperative day 
secondary to a respiratory arrest. Incessant ventricular tachy- 
cardia occurred in Patient 9 as well. Again, echocardiography 
demonstrated a structurally normal heart. After unsuccessful 
therapy with flecainide and amiodarone, an electrophysiologic 
study demonstrated the earliest activation of the ventricular 
tachycardia tobe in the posterior left ventricle just below the 
mitral valve. A hamartoma was surgically removed from the 
posterior left ventricle below the mitral valve. 
Side effects. No proarrhythmia occurred, and none of the 
infants required a pacemaker. The corrected QT intervals 
varied from 0.440 to 0.488 ms. No side effects occurred that 
necessitated discontinuing combination therapy. 
All of the infants had normal eft ventricular dimensions 
and fractional shortening by echocardiography before com- 
bined flecainide and amiodarone therapy, except for Patient 7 
with incessant ventricular tachycardia. During combined ther- 
apy, all infants continued to demonstrate normal eft ventric- 
ular dimensions and fractional shortening. 
Follow-up information. The average length of flecainide 
and amiodarone therapy in the seven infants with successfully 
controlled tachyarrhythmias was 6 months (range 3 to 17) 
(Table 2). Three of seven infants are in sinus rhythm and 
receive no antiarrhythmic agents. Tachyarrhythmias in three of 
seven infants are controlled with single-drug therapy, and the 
remaining infant is in sinus rhythm with combined flecainide 
and amiodarone therapy. None of the seven infants who 
achieved effective tachyarrhythmia control with flecainide and 
amiodarone r quired interventional therapy. 
Discuss ion  
Combined flecainide and amiodarone therapy has been 
demonstrated to effectively control refractory tachyarrhyth- 
mias in adults. Because amiodarone may increase flecainide 
plasma levels by -30%, it is recommended to decrease the 
initial daily dose of flecainide by 20% to 50% (29-31). In our 
patients, it appeared reasonable to decrease the initial daily 
dose of flecainide by one-third when it was used in combina- 
tion with amiodarone while flecainide serum trough levels 
were monitored closely. 
Role of flecainide and amiodarone in infants. Combined 
therapy with flecainide and amiodarone successfully controlled 
tachyarrhythmias that were refractory to all previous medical 
therapy in seven infants. For a few of these infants this medical 
regimen may have been life-saving and prevented the need for 
early interventional therapy. This is most likely the case for 
three infants with congenital junctional ectopic tachycardia 
(Patients 4 to 6). 
The combination of flecainide and amiodarone appears to 
be effective for controlling refractory ectopic focus tachycar- 
dias, in particular tachycardias with an atrial or junctional 
focus. Congenital junctional ectopic tacbycardia can be very 
resistant to medical therapy and carries a high risk of mortality 
if uncontrolled (32,33). All three of the infants in this study 
with congenital junctional ectopic tachycardia survived, and 
two are now in sinus rhythm with no antiarrhythmic therapy. 
Tachyarrbthmia in the remaining infant is well controlled by 
amiodarone therapy alone with no symptoms and normal 
echocardiographic findings. 
Ventricular tachycardia due to myocardial tumors generally 
does not respond to standard therapies, although combination 
antiarrhytbmic therapy may be effective in some patients (34). 
Flecainide and amiodarone did not suppress ventricular tachy- 
cardia in two infants in the present study; however, both had 
slowing of their ventricular tachycardia, llowing stabilization 
before successful surgical intervention. The infant with ventric- 
ular tachycardia who underwent AV septal defect repair did 
respond to flecainide and amiodarone. Even though the com- 
bination therapy was effective in this infant, we do not gener- 
ally recommend the use of flecainide in children with a 
structurally abnormal heart. 
Conclusions. Although the present study included a small 
number of infants, results with combined flecainide and amio- 
darone therapy are encouraging. For the infants reported here, 
combined flecainide and amiodarone therapy appeared to be 
safe and effective for controlling refractory tachyarrhythmias. 
Supraventricular tachycardias, in particular those secondary to
an ectopic focus mechanism, responded well to this regimen. 
1198 FENRICH ET AL. JACC Vol. 25, No. 5 
FLECAINIDE AND AMIODARONE IN INFANTS April 1995:1195-8 
The ectopic focus tachycardias are presumably secondary to 
abnormal automaticity. Because flecainide and amiodarone 
have different effects on the action potential, it is likely that 
together they suppress the mechanism responsible for abnor- 
mal automaticity in these infants. Without in vitro data for this 
drug combination, it is difficult to speculate on the cellular 
mechanism responsible. Ventricular tachycardias, although 
affected by these agents in combination, were not as success- 
fully managed and may ultimately require interventional ther- 
apy. In infants with tachyarrhythmias in which conventional 
medical therapy fails, combined therapy with flecainide and 
amiodarone should be considered before attempting interven- 
tional therapy because the need for interventional therapy may 
be prevented or delayed until the child is older. 
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